NEW YORK , Oct. 29, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN ) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Elanco investors who were adversely affected by alleged securities fraud between November 7, 2023 and June 26, 2024 .
Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/elanco-animal-health-incorporated-lawsuit-submission-form?prid=109644&wire=4 ELAN investors may also contact Joseph E. Levi, Esq.
via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Zenrelia, a once-daily oral inhibitor for canine dermatology, was less safe than the Company had led investors to believe; (ii) Elanco was unlikely to meet its own previously issued timeline for the U.S.
approval and commercial launch of both Zenrelia and Credelio Quattro, a broad spectrum parasiticide product for dogs; (iii) accordingly, the Company's business and/or financial prospects were overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times. WHAT'S NEXT? If you suffered a loss in Elanco during the relevant time frame, you have until December 6, 2024 to request that the Court appoint you as lead plaintiff. Your ability.
